What is the difference between BPC-157 and TB-500?
BPC-157 addresses angiogenesis and fibroblast recruitment. TB-500 addresses cellular migration through actin regulation. Different layers of the tissue-repair cascade.
Last reviewed 2026-07-13
Read the answer
BPC-157 is a synthetic 15-amino-acid fragment of a protein isolated from human gastric juice. Its distinctive preclinical mechanism centres on VEGF-driven angiogenesis, fibroblast migration, and modulation of the nitric oxide system. In tissue-repair terms, BPC-157 addresses vascular supply and fibroblast recruitment — the metabolic support and cellular workforce of the repair site. The Sikiric lab in Zagreb has produced 25+ years of preclinical work on tendon, gut, muscle, bone, and vascular healing endpoints. The FDA added BPC-157 to a compounding-agent concern list in 2023 citing insufficient clinical data.
TB-500 is a synthetic 17-amino-acid fragment of thymosin β4. Its distinctive mechanism is regulation of cellular migration through actin sequestration and cytoskeletal dynamics — the biology that lets stem cells and repair cells physically move through tissue to injury sites. Recombinant thymosin β4 has had human phase-1/2 clinical development for cardiac and wound-healing contexts (RegeneRx programme), which places TB-500 closer to the clinical evidence tier than BPC-157 though still not at approved-drug level.
The two peptides are commonly combined (BPC-157 + TB-500 blend) because they address different rate-limiting steps in the tissue-repair cascade. BPC-157 gets the vasculature built; TB-500 gets the right cells to the right places. When paired with GHK-Cu (gene expression) and KPV (inflammation control) in Klow, all four layers of the cascade are addressed simultaneously.
Related on Healthy Mango
Related research blends
Related guides
Related comparisons
Related research categories
References
- BPC 157 and Standard Angiogenic Growth Factors — Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing· Seiwerth S, Milavic M, Vukojevic J, et al. · 2019
- Isolation of a biologically active fraction from bovine thymus (thymosin fraction 5) — the discovery paper for the thymosin peptide family· Goldstein AL, Guha A, Zatz MM, Hardy MA, White A · 1972
Question
Related questions
Other questions that touch the same biology, evidence, or laboratory concepts.
What makes GHK-Cu different from KPV?
GHK-Cu is a copper-carrier tripeptide that drives ECM remodelling through broad transcriptional modulation. KPV is a tripeptide fragment of α-MSH that suppresses inflammation through NF-κB inhibition. Different mechanisms, different roles in tissue-repair blends.
Why is semaglutide approved but retatrutide is not?
Semaglutide has completed its phase-3 program and reached approval. Retatrutide is still in phase-3 development — the compound is investigational, not rejected. Approval is expected pending phase-3 completion.
What is the difference between CJC-1295 and CJC-1295 DAC?
The 'DAC' variant uses drug-affinity-complex chemistry that covalently binds to serum albumin, extending half-life from hours to about a week. The 'No DAC' variant retains the shorter half-life and pulsatile pharmacology.
Why is PT-141 approved but Melanotan II is not?
PT-141 (bremelanotide) is a structurally-refined variant of Melanotan II with more selective MC4R activity. It completed a phase-3 program in female HSDD and was FDA-approved as Vyleesi in 2019. Melanotan II has no completed clinical program in any indication.